

REMARKS/ARGUMENTS

Restriction/Election Requirement:

In the Office Action, the Examiner has required an election be made under 35 U.S.C. §121 among fifteen groups among fifteen (15) groups of claims as follows:

Group I: Claims 1, 6-19 and 34-47 drawn to a method of treating cutaneous T-cell lymphoma, classified in class 514, subclass 675.

Group II: Claims 2 and 20-33, drawn to a method of treating cutaneous T-cell lymphoma, classified in class 514, subclass 277.

Group III: Claim 3, drawn to a method of treating cutaneous T-cell lymphoma, classified in class 514, subclass 645.

Group IV: Claim 5, drawn to a method of treating cutaneous T-cell lymphoma, classified in class 514, subclass 579.

Group V: Claims 48, 53-66 and 81-94 drawn to a method of treating peripheral T-cell lymphoma, classified in class 514, subclass 675.

Group VI: Claims 49 and 67-80 drawn to a method of treating peripheral T-cell lymphoma, classified in class 514, subclass 277.

Group VII: Claim 50, drawn to a method of treating peripheral T-cell lymphoma, classified in class 514, subclass 645.

Group VIII: Claim 52, drawn to a method of treating peripheral T-cell lymphoma, classified in class 514, subclass 579.

Group IX: Claims 95, 100-114 and 130-144 drawn to a method of treating head and neck cancer, classified in class 514, subclass 675.

Group X: Claims 96 and 115-129 drawn to a method of treating head and neck cancer, classified in class 514, subclass 277.

Group XI: Claim 97, drawn to a method of treating head and neck cancer, classified in class 514, subclass 645.

Group XII: Claim 99, drawn to a method of treating head and neck cancer, classified in class 514, subclass 645.

Group XIII: Claims 145-186, drawn to a method of inducing cell differentiation, classified in class 514, subclass 675.

Group XIV: Claims 187-207, drawn to a method of inducing cell growth arrest, classified in class 514, subclass 675.

Group XV: Claims 208-228, drawn to a method of selectively inducing apoptosis, classified in class 514, subclass 675.

In response, Applicants elect **Group I**, claims 1, 6-19 and 34-47 drawn to a method of treating cutaneous T-cell lymphoma comprising administering to a subject an effective amount of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA), for further prosecution in this application. These claims are classified in class 514, subclass 675. Applicants note that the election is made for the purpose of examination of the claims only, and that Applicants maintain the right to have the full scope of the claims in Groups II-XV as written, examined on the merits in the future applications.


CONCLUSION

Favorable action on the merits is respectfully requested. If there are any questions regarding this Response, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Applicants believe that this Response is timely and no additional fees are due with the filing of this Response. However, if any additional fees are required or if any funds are due, the USPTO is authorized to charge or credit Deposit Account Number: **50-0311**, Customer Number: **35437**, Reference Number: **24852-501 CIP2**.

Respectfully submitted,

Date: October 6, 2006


Ivor R. Elrifi, Reg. No. 39,529
Ilona Gont, Reg. No. 58,714
MINTZ LEVIN COHEN FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Telephone: (212) 935-3000
Telefax: (212) 983-3115